Your browser doesn't support javascript.
loading
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML.
de Botton, Stéphane; Cluzeau, Thomas; Vigil, Carlos; Cook, Rachel J; Rousselot, Philippe; Rizzieri, David A; Liesveld, Jane L; Fenaux, Pierre; Braun, Thorsten; Banos, Anne; Jurcic, Joseph G; Sekeres, Mikkael A; Savona, Michael R; Roboz, Gail J; Bixby, Dale; Madigan, Kate; Volkert, Angela; Stephens, Kristin; Kang-Fortner, Qing; Baker, Kristen; Paul, Sofia; McKeown, Michael; Carulli, John; Eaton, Matthew; Hodgson, Graeme; Fiore, Christopher; Kelly, Michael J; Roth, David A; Stein, Eytan M.
Afiliação
  • de Botton S; Institut Gustave Roussy, Paris, France.
  • Cluzeau T; Côte d'Azur Université, Centre Hospitalier Universitaire de Nice Hôpital, Nice, France.
  • Vigil C; Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL.
  • Cook RJ; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
  • Rousselot P; Hôpital André Mignot, Centre Hospitalier de Versailles, Le Chesnay, France.
  • Rizzieri DA; Novant Health Cancer Institute, Winston-Salem, NC.
  • Liesveld JL; University of Rochester Medical Center, Rochester, NY.
  • Fenaux P; Hôpital Saint-Louis, Paris, France.
  • Braun T; Centre Hospitalier Universitaire Hôpital Avicenne, Bobigny, France.
  • Banos A; Centre Hospitalier de la Côte Basque, Bayonne, France.
  • Jurcic JG; Columbia University Irving Medical Center, New York, NY.
  • Sekeres MA; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
  • Savona MR; Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Vanderbilt University, Nashville, TN.
  • Roboz GJ; Weill Cornell Medicine, New York, NY.
  • Bixby D; Rogel Cancer Center, University of Michigan, Ann Arbor, MI.
  • Madigan K; Syros Pharmaceuticals, Inc, Cambridge, MA.
  • Volkert A; Syros Pharmaceuticals, Inc, Cambridge, MA.
  • Stephens K; Syros Pharmaceuticals, Inc, Cambridge, MA.
  • Kang-Fortner Q; Syros Pharmaceuticals, Inc, Cambridge, MA.
  • Baker K; Syros Pharmaceuticals, Inc, Cambridge, MA.
  • Paul S; Syros Pharmaceuticals, Inc, Cambridge, MA.
  • McKeown M; Syros Pharmaceuticals, Inc, Cambridge, MA.
  • Carulli J; Syros Pharmaceuticals, Inc, Cambridge, MA.
  • Eaton M; Syros Pharmaceuticals, Inc, Cambridge, MA.
  • Hodgson G; Syros Pharmaceuticals, Inc, Cambridge, MA.
  • Fiore C; Syros Pharmaceuticals, Inc, Cambridge, MA.
  • Kelly MJ; Syros Pharmaceuticals, Inc, Cambridge, MA.
  • Roth DA; Syros Pharmaceuticals, Inc, Cambridge, MA.
  • Stein EM; Memorial Sloan Kettering Cancer Center, New York, NY.
Blood Adv ; 7(9): 1858-1870, 2023 05 09.
Article em En | MEDLINE | ID: mdl-36477975
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Leucemia Mieloide Aguda / Leucemia Promielocítica Aguda Limite: Humans Idioma: En Revista: Blood Adv Ano de publicação: 2023 Tipo de documento: Article País de afiliação: França
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Leucemia Mieloide Aguda / Leucemia Promielocítica Aguda Limite: Humans Idioma: En Revista: Blood Adv Ano de publicação: 2023 Tipo de documento: Article País de afiliação: França